Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • BACKGROUND: There are limited contemporary data on the early use of clopidogrel or glycoprotein (Gp) IIb/IIIa inhibitors, alone versus combination therapies, in non-ST-elevation acute coronary syndrome (NSTE-ACS). METHODS: This study included 5,806 Canadian NSTE-ACS patients with elevated cardiac biomarker and/or ST deviation on presentation in the prospective GRACE between 2003-2007. We stratified the study population according to the management strategy (non-invasive vs invasive) and into low-(GRACE risk score or=141). RESULTS: Overall, 3,893 patients (67.1%) received early (


  • Banihashemi, Behnam
  • Goodman, Shaun G
  • Yan, Raymond T
  • Welsh, Robert C
  • Mehta, Shamir
  • Montalescot, Gilles
  • Kornder, Jan M
  • Wong, Graham C
  • Gyenes, Gabor
  • Steg, Ph Gabriel
  • Yan, Andrew T

publication date

  • December 2009

has subject area